Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
…, S Teraoka, N Matsumoto, Y Shiraishi… - Cancer …, 2022 - Wiley Online Library
Considering the increasing number of identified driver oncogene alterations, additional
genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (…
genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (…
[HTML][HTML] Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
H Li, K Takayama, S Wang, Y Shiraishi… - Cancer chemotherapy …, 2014 - Springer
Purpose Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI),
and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are promising …
and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are promising …
Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies
Y Yoneshima, K Tanaka, Y Shiraishi, K Hata… - Lung Cancer, 2019 - Elsevier
Objectives To examine the possible effects of antinuclear antibodies (ANA) on the safety
and efficacy of programmed cell death–1 (PD-1) inhibitors in patients with advanced non–small …
and efficacy of programmed cell death–1 (PD-1) inhibitors in patients with advanced non–small …
A randomized comparison of nivolumab versus Nivolumab+ docetaxel for previously treated advanced or recurrent ICI-naïve non–small cell lung cancer: torg1630
…, Y Nakamura, Y Kawashima, N Furuya, Y Shiraishi… - Clinical Cancer …, 2022 - AACR
Purpose: The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may
enhance antitumor effects. We conducted an open-label randomized phase II/III study to …
enhance antitumor effects. We conducted an open-label randomized phase II/III study to …
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors
K Furuyama, T Harada, E Iwama, Y Shiraishi… - Cancer …, 2013 - Wiley Online Library
The presence of epidermal growth factor receptor ( EGFR ) somatic mutations in non‐small‐cell
lung cancer patients is associated with response to treatment with EGFR ‐tyrosine …
lung cancer patients is associated with response to treatment with EGFR ‐tyrosine …
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial
…, Y Sato, T Kurata, S Sugawara, Y Shiraishi… - JAMA …, 2023 - jamanetwork.com
Importance Administration of durvalumab after concurrent chemoradiotherapy is the standard
treatment of unresectable, locally advanced non–small cell lung cancer (NSCLC); however…
treatment of unresectable, locally advanced non–small cell lung cancer (NSCLC); however…
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus …
Y Shiraishi, T Hakozaki, S Nomura, T Kataoka… - Clinical Lung Cancer, 2022 - Elsevier
Background First-line treatment of non–small cell lung cancer (NSCLC) has undergone a
paradigm shift to platinum combination chemotherapy together with an immune checkpoint …
paradigm shift to platinum combination chemotherapy together with an immune checkpoint …
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer
…, G Toyokawa, T Yoshida, Y Shiraishi… - European Journal of …, 2015 - academic.oup.com
OBJECTIVES The impact of epidermal growth factor receptor (EGFR) status and the use of
EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in …
EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in …
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized …
Y Shiraishi, J Kishimoto, S Sugawara, H Mizutani… - JAMA …, 2024 - jamanetwork.com
Importance The combination of an antibody to programmed cell death-1 (PD-1) or to its
ligand (PD-L1) with chemotherapy is the standard first-line treatment for metastatic non–small …
ligand (PD-L1) with chemotherapy is the standard first-line treatment for metastatic non–small …
[HTML][HTML] Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer
…, K Tanaka, E Iwama, Y Shiraishi… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Immunogenic cell death (ICD) characterized by the release of damage-associated
molecular patterns (DAMPs) from dying cancer cells may contribute to the synergistic …
molecular patterns (DAMPs) from dying cancer cells may contribute to the synergistic …